Naliean Therapeutics

Naliean Therapeutics is an oncology-focused biotech startup developing next-generation antibody-drug conjugates built on a nanobody-based multispecific platform. The company emphasizes modular ADC engineering, including multispecific targeting and dual-payload conjugation, to improve tumor penetration, selectivity, and therapeutic index versus conventional IgG-based ADCs. Its disclosed lead program, NL019, is a dual-target TROP2/Nectin-4 nanobody-based ADC for solid tumors. Public materials indicate that Naliean is focused on discovery and early-stage clinical development, with operations in China and a preclinical pipeline centered on cancer therapeutics.